Literature DB >> 19647123

Changes in the endocannabinoid system may give insight into new and effective treatments for cancer.

Gianfranco Alpini1, Sharon Demorrow.   

Abstract

The endocannabinoid system comprises specific cannabinoid receptors such as Cb1 and Cb2, the endogenous ligands (anandamide and 2-arachidonyl glycerol among others) and the proteins responsible for their synthesis and degradation. This system has become the focus of research in recent years because of its potential therapeutic value several disease states. The following review describes our current knowledge of the changes that occur in the endocannabinoid system during carcinogenesis and then focuses on the effects of anandamide on various aspects of the carcinogenic process such as growth, migration, and angiogenesis in tumors from various origins.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19647123      PMCID： PMC2791688          DOI： 10.1016/S0083-6729(09)81018-2

Source DB:  PubMed          Journal:  Vitam Horm        ISSN： 0083-6729            Impact factor:   3.421


  64 in total

1.  AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo.

Authors:  Serena Zacchigna; Lorena Zentilin; Monica Morini; Raffaella Dell'Eva; Douglas M Noonan; Adriana Albini; Mauro Giacca
Journal:  Cancer Gene Ther       Date:  2004-01       Impact factor: 5.987

2.  High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.

Authors:  T C Islam; A C Asplund; J M Lindvall; L Nygren; J Liden; E Kimby; B Christensson; C I E Smith; B Sander
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

3.  Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1.

Authors:  Emmanuel Contassot; Rick Wilmotte; Mirna Tenan; Marie-Claude Belkouch; Valérie Schnüriger; Nicolas de Tribolet; Karim Burkhardt; Pierre-Yves Dietrich; Karim Bourkhardt
Journal:  J Neuropathol Exp Neurol       Date:  2004-09       Impact factor: 3.685

4.  R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts.

Authors:  Burkhard Hinz; Robert Ramer; Karin Eichele; Ulrike Weinzierl; Kay Brune
Journal:  Biochem Biophys Res Commun       Date:  2004-11-12       Impact factor: 3.575

5.  Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production.

Authors:  Murielle Mimeault; Nicole Pommery; Nicole Wattez; Christian Bailly; Jean-Pierre Hénichart
Journal:  Prostate       Date:  2003-06-15       Impact factor: 4.104

6.  A new strategy to block tumor growth by inhibiting endocannabinoid inactivation.

Authors:  Maurizio Bifulco; Chiara Laezza; Marta Valenti; Alessia Ligresti; Giuseppe Portella; Vincenzo DI Marzo
Journal:  FASEB J       Date:  2004-08-02       Impact factor: 5.191

7.  Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor.

Authors:  Stefan Hart; Oliver M Fischer; Axel Ullrich
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

8.  Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1.

Authors:  Emmanuel Contassot; Mirna Tenan; Valérie Schnüriger; Marie-Françoise Pelte; Pierre-Yves Dietrich
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

9.  Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes.

Authors:  Jan Joseph; Bernd Niggemann; Kurt S Zaenker; Frank Entschladen
Journal:  Cancer Immunol Immunother       Date:  2004-03-18       Impact factor: 6.968

10.  The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner.

Authors:  Meritxell Alberich Jordà; Nazik Rayman; Marjolein Tas; Sandra E Verbakel; Natalia Battista; Kirsten van Lom; Bob Löwenberg; Mauro Maccarrone; Ruud Delwel
Journal:  Blood       Date:  2004-03-23       Impact factor: 22.113
View more
  12 in total

1.  Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses.

Authors:  Katherine E Hanlon; Todd W Vanderah
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

2.  Characterization of endocannabinoid-mediated induction of myeloid-derived suppressor cells involving mast cells and MCP-1.

Authors:  Austin R Jackson; Venkatesh L Hegde; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Leukoc Biol       Date:  2013-12-06       Impact factor: 4.962

3.  2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease.

Authors:  Marika Cordaro; Rosalba Siracusa; Rosalia Crupi; Daniela Impellizzeri; Alessio Filippo Peritore; Ramona D'Amico; Enrico Gugliandolo; Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Mol Neurobiol       Date:  2018-04-14       Impact factor: 5.590

4.  Revisiting CB1 receptor as drug target in human melanoma.

Authors:  István Kenessey; Balázs Bánki; Agnes Márk; Norbert Varga; József Tóvári; Andrea Ladányi; Erzsébet Rásó; József Tímár
Journal:  Pathol Oncol Res       Date:  2012-03-24       Impact factor: 3.201

5.  Cannabinoid CB₁ receptor is downregulated in clear cell renal cell carcinoma.

Authors:  Gorka Larrinaga; Begoña Sanz; Itxaro Pérez; Lorena Blanco; María L Cándenas; Francisco M Pinto; Javier Gil; José I López
Journal:  J Histochem Cytochem       Date:  2010-09-17       Impact factor: 2.479

6.  Endocannabinoid System in Polycystic Kidney Disease.

Authors:  Jost Klawitter; Cristina Sempio; Matthew J Jackson; Peter H Smith; Katharina Hopp; Michel Chonchol; Berenice Y Gitomer; Uwe Christians; Jelena Klawitter
Journal:  Am J Nephrol       Date:  2022-03-09       Impact factor: 4.605

7.  Bimatoprost in the treatment of eyelash hypotrichosis.

Authors:  Simon K Law
Journal:  Clin Ophthalmol       Date:  2010-04-26

8.  Inhibition of fatty acid amide hydrolase activates Nrf2 signalling and induces heme oxygenase 1 transcription in breast cancer cells.

Authors:  H Li; J T Wood; K M Whitten; S K Vadivel; S Seng; A Makriyannis; H K Avraham
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

9.  Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes.

Authors:  Vyvyca J Walker; Alisha P Griffin; Dagan K Hammar; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2016-03-21       Impact factor: 4.030

10.  Lipid mediators involved in the oxidative stress and antioxidant defence of human lung cancer cells.

Authors:  Agnieszka Gęgotek; Jacek Nikliński; Neven Žarković; Kamelija Žarković; Georg Waeg; Wojciech Łuczaj; Radosław Charkiewicz; Elżbieta Skrzydlewska
Journal:  Redox Biol       Date:  2016-08-20       Impact factor: 11.799
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.